Provided by Tiger Trade Technology Pte. Ltd.

Insmed

101.74
-3.4900-3.32%
Post-market: 103.001.26+1.23%19:47 EDT
Volume:3.16M
Turnover:323.85M
Market Cap:22.22B
PE:-24.89
High:104.80
Open:103.87
Low:101.60
Close:105.23
52wk High:212.75
52wk Low:90.39
Shares:218.38M
Float Shares:216.82M
Volume Ratio:0.84
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0882
EPS(LYR):-6.4200
ROE:-87.22%
ROA:-22.17%
PB:29.33
PE(LYR):-15.85

Loading ...

Insmed (INSM) Reaffirms Outlook As Its Undervalued Narrative Faces A Fresh Test

Simply Wall St.
·
Oct 06

Movement Alert|Insmed Intraday Decline 5.71% in Regular Trading, CFO to Step Down

Market Focus
·
Oct 05

Insmed Chief Financial Officer Sara Bonstein to Step Down

MT Newswires Live
·
Oct 05

Insmed CFO Sara Bonstein Steps Down Oct. 30

Reuters
·
Oct 05

Insmed Incorporated - Reaffirms Full-Year 2026 Financial Guidance

THOMSON REUTERS
·
Oct 05

Insmed - Sara Bonstein to Step Down as CFO

THOMSON REUTERS
·
Oct 05

Insmed Announces CFO Transition

THOMSON REUTERS
·
Oct 05

Insmed: Overweight Rating Reaffirmed as Brinsupri Momentum Drives Raised 2026 Guidance; Price Target Maintained at $218

TIPRANKS
·
Oct 03

Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul

Reuters
·
Oct 02

Insmed Price Target Cut to $207.00/Share from $237.00 by Barclays

Dow Jones
·
Sep 30

Barclays Remains a Buy on Insmed (INSM)

TIPRANKS
·
Sep 30

Insmed: Brinsupri Launch Momentum Supports Overweight Rating and Unchanged $218 Price Target

TIPRANKS
·
Sep 28

Insmed Price Target Announced at $188.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

Insmed resumed with a Buy at Goldman Sachs

TIPRANKS
·
Sep 24

Mizuho Securities Sticks to Its Buy Rating for Insmed (INSM)

TIPRANKS
·
Sep 23

Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214

TIPRANKS
·
Sep 22

Insmed Rises on FDA Priority Review for Lung Disease Drug

Reuters
·
Sep 21

Insmed says FDA grants Priority Review to sNDA for Arikayce

TIPRANKS
·
Sep 21

FDA Grants Priority Review to Insmed's Snda for Arikayce® (Amikacin Liposome Inhalation Suspension) for Treatment of Mac Lung Disease with Pdufa Target Action Date Set for January 28, 2027

THOMSON REUTERS
·
Sep 21

Insmed: Brinsupri Launch Trends Support Growth Outlook; Buy Rating and $218 Price Target Reaffirmed

TIPRANKS
·
Sep 21